NKGen Biotech (NKGN) Competitors $0.57 +0.12 (+27.12%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.50 -0.07 (-12.20%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends NKGN vs. VIGL, DERM, TCRX, ARTV, PROC, RANI, ATOS, CRBP, CLYM, and ZURAShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Vigil Neuroscience (VIGL), Journey Medical (DERM), TScan Therapeutics (TCRX), Artiva Biotherapeutics (ARTV), Procaps Group (PROC), Rani Therapeutics (RANI), Atossa Therapeutics (ATOS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Vigil Neuroscience Journey Medical TScan Therapeutics Artiva Biotherapeutics Procaps Group Rani Therapeutics Atossa Therapeutics Corbus Pharmaceuticals Climb Bio Zura Bio NKGen Biotech (NYSE:NKGN) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Do analysts rate NKGN or VIGL? Vigil Neuroscience has a consensus price target of $19.75, suggesting a potential upside of 551.82%. Given Vigil Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Vigil Neuroscience is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vigil Neuroscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of NKGN or VIGL? 76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 33.0% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, NKGN or VIGL? NKGen Biotech has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Does the MarketBeat Community favor NKGN or VIGL? Vigil Neuroscience received 31 more outperform votes than NKGen Biotech when rated by MarketBeat users. CompanyUnderperformOutperformNKGen BiotechN/AN/AVigil NeuroscienceOutperform Votes3183.78% Underperform Votes616.22% Is NKGN or VIGL more profitable? NKGen Biotech's return on equity of 0.00% beat Vigil Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Vigil Neuroscience N/A -83.89%-65.34% Does the media prefer NKGN or VIGL? In the previous week, NKGen Biotech had 3 more articles in the media than Vigil Neuroscience. MarketBeat recorded 4 mentions for NKGen Biotech and 1 mentions for Vigil Neuroscience. NKGen Biotech's average media sentiment score of 0.00 equaled Vigil Neuroscience'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NKGen Biotech 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vigil Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, NKGN or VIGL? Vigil Neuroscience has lower revenue, but higher earnings than NKGen Biotech. Vigil Neuroscience is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen Biotech$80K319.99-$82.94M-$5.08-0.11Vigil NeuroscienceN/AN/A-$82.64M-$2.06-1.47 SummaryVigil Neuroscience beats NKGen Biotech on 10 of the 14 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$25.60M$3.13B$5.77B$20.07BDividend YieldN/A1.57%4.78%3.65%P/E Ratio-0.1130.1126.4634.90Price / Sales319.99386.73453.2515.64Price / CashN/A183.5344.0420.85Price / Book-0.213.567.634.92Net Income-$82.94M-$71.72M$3.18B$1.02B7 Day Performance-9.75%-2.46%-1.91%-1.05%1 Month Performance12.08%-0.25%-0.19%-1.09%1 Year Performance-43.05%-12.31%16.70%13.70% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen BiotechN/A$0.57+27.1%N/A-40.1%$25.60M$80,000.00-0.11N/ANews CoverageGap UpHigh Trading VolumeVIGLVigil Neuroscience3.1918 of 5 stars$2.76+1.8%$19.75+615.6%+0.3%$112.83MN/A-1.3440DERMJourney Medical2.5229 of 5 stars$5.24+1.0%$9.67+84.5%+38.0%$109.46M$79.18M-5.5790TCRXTScan Therapeutics2.4626 of 5 stars$2.05+0.5%$11.25+448.8%-68.8%$109.41M$9.36M-1.93100ARTVArtiva BiotherapeuticsN/A$4.44+10.7%$21.00+373.0%N/A$107.85MN/A0.0081News CoveragePROCProcaps GroupN/A$0.95-40.3%N/A-73.4%$107.18M$409.92M0.004,900News CoverageGap DownHigh Trading VolumeRANIRani Therapeutics3.5936 of 5 stars$1.85+0.5%$12.33+566.7%-49.2%$105.99MN/A-1.75110Positive NewsATOSAtossa Therapeutics1.3108 of 5 stars$0.83+1.9%$7.00+743.2%-21.3%$104.44MN/A-3.778Positive NewsCRBPCorbus Pharmaceuticals4.0441 of 5 stars$8.51-10.2%$61.38+621.2%-69.9%$103.65MN/A-1.8140Analyst ForecastHigh Trading VolumeCLYMClimb Bio2.4906 of 5 stars$1.52-4.4%$10.00+557.9%N/A$102.17MN/A-0.719Gap UpZURAZura Bio2.8476 of 5 stars$1.55+3.3%$15.80+919.4%-62.0%$101.20MN/A0.003Gap Up Related Companies and Tools Related Companies Vigil Neuroscience Alternatives Journey Medical Alternatives TScan Therapeutics Alternatives Artiva Biotherapeutics Alternatives Procaps Group Alternatives Rani Therapeutics Alternatives Atossa Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Climb Bio Alternatives Zura Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NKGN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKGN Stock Alerts